GAMIDA CELL LTD.

(GMDA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Gamida Cell Plans Rolling Submission of Biologics License Application for Bone Marrow Transplant Product; Shares Rise Pre-Bell

01/19/2022 | 07:56am EDT


ę MT Newswires 2022
All news about GAMIDA CELL LTD.
04:31pGamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences..
BU
05/12GAMIDA CELL LTD. Management's Discussion and Analysis of Financial Condition and Resul..
AQ
05/10TRANSCRIPT : Gamida Cell Ltd., Q1 2022 Earnings Call, May 10, 2022
CI
05/10Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/10Gamida Cell Reports First Quarter 2022 Financial Results and Provides Company Update
BU
05/05Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK)..
BU
05/05Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK)..
CI
05/03Gamida Cell Announces the Date of Its First Quarter 2022 Financial Results and Webcast
BU
04/27Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study..
BU
04/27Gamida Cell Ltd. Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 ..
CI
More news
Analyst Recommendations on GAMIDA CELL LTD.
More recommendations
Financials (USD)
Sales 2022 1,85 M - -
Net income 2022 -78,4 M - -
Net Debt 2022 62,0 M - -
P/E ratio 2022 -1,92x
Yield 2022 -
Capitalization 141 M 141 M -
EV / Sales 2022 110x
Capi. / Sales 2023 4,19x
Nbr of Employees 167
Free-Float 69,8%
Chart GAMIDA CELL LTD.
Duration : Period :
Gamida Cell Ltd. Technical Analysis Chart | GMDA | IL0011552663 | MarketScreener
Technical analysis trends GAMIDA CELL LTD.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 2,36 $
Average target price 13,83 $
Spread / Average Target 486%
EPS Revisions
Managers and Directors
Julian Adams Chief Executive Officer & Director
Shai Lankry Chief Financial Officer
Robert I. Blum Chairman
Ronit Simantov Chief Medical & Scientific Officer
Yona Geffen Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
GAMIDA CELL LTD.-7.09%141
GILEAD SCIENCES, INC.-14.28%78 068
REGENERON PHARMACEUTICALS, INC.3.72%70 575
VERTEX PHARMACEUTICALS15.74%65 005
WUXI APPTEC CO., LTD.-16.20%42 275
BIONTECH SE-41.35%36 745